You are here

I- Corps Administrative Supplement to Novel Reagents for Breast Tumor SPECT Imaging R41CA217546

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA217546-01
Agency Tracking Number: R41CA217546
Amount: $275,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCI
Solicitation Number: PA18-517
Timeline
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-04-07
Award End Date (Contract End Date): 2018-08-15
Small Business Information
505 COAST BLVD S, STE 209
La Jolla, CA 92037-4614
United States
DUNS: 080202185
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MICHAEL LEVIN
 (858) 450-9999
 mlevin@prism-sd.org
Business Contact
 L JEAN REMMER
Phone: (858) 450-9999
Email: jremmer@cavatar-sd.com
Research Institution
 CAVATAR, LLC
 
505 COAST BLVD S, STE 209
LA JOLLA, CA 92037-4614
United States

 Domestic Nonprofit Research Organization
Abstract

PROJECT SUMMARY
Early cancer detection and diagnosis are critical for patient survival and treatment successFor the imaging of
breast and other solid tumorsthe diagnostic power of advanced imaging techniques such as SPECT could
benefit tremendously from improved contrast agents that rapidly and selectively accumulate in tumor lesions and
produce high tumor to background signal ratiosWe are developing a novel contrast imaging agent for use in
breast cancer and other solid tumors that can enhance image resolution by selectively targeting and delivering
imaging probes directly into tumor lesions with little or no accumulation in surrounding normal tissueTo do thiswe are conjugatingmTc to an antibody based delivery platform that exploits a caveolae mediated
transvascular transport pathway to target and rapidly deliver cargo across the restrictive vascular endothelium
directly into tumor lesions following intravenous injectionThis novel imaging probe will be optimized and then
tested in vivo before undergoing the necessary preparations to undergo clinical testingWith assistance from the
I Corps programwe will further develop and refine our commercialization strategies as a necessary step towards
bringing this innovative technology to the clinic and the marketplace PROJECT NARRATIVE
Cavatar is developing a novel imaging reagent which will rapidlyselectivelyand specifically accumulate in solid
tumor lesions after an intravenous injectionproviding enhanced image resolutionThis reagent can enable
accurate imaging of breast and other solid tumors using existing equipment for screening or diagnostic
applicationsThis technology will improve diagnostic accuracy of imagingallow for more accurate stratification
of patients and selection of treatment choicesand reduce the need to perform additional diagnostic procedures

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government